112 results match your criteria: "Liver Institute Northwest[Affiliation]"

Background And Aims: Primary biliary cholangitis (PBC) is a rare, progressive liver disease. Obeticholic acid (OCA) received accelerated approval for treating patients with PBC in whom ursodeoxycholic acid (UDCA) failed, based on a surrogate endpoint of reduction in alkaline phosphatase. Analysis of the long-term safety extension with 2 external control groups demonstrated a significant increase in event-free survival in OCA-treated patients.

View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel disease (IBD) significantly impacts patient health, with recent studies linking sarcopenia (muscle loss) to decreased quality of life and poor clinical outcomes.
  • An analysis of over 1.5 million hospitalizations showed that patients with sarcopenia had higher rates of in-hospital mortality (4.2% vs. 1.2%), ICU admissions, and required more surgeries compared to those without sarcopenia.
  • The study concludes that managing sarcopenia is essential for improving health outcomes in IBD patients, as it was associated with a nearly threefold increase in the risk of dying during hospitalization.
View Article and Find Full Text PDF

Objective: The only curative treatment for patients with end-stage liver disease (ESLD) is liver transplantation (LT). Patients with ESLD can develop delirium due to multiple etiologies. In this study, we aimed to assess the prevalence and impact of delirium on outcomes and resource utilization among hospitalized patients undergoing LT.

View Article and Find Full Text PDF
Article Synopsis
  • Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare chronic liver diseases that can lead to severe liver damage if not treated.
  • Ursodeoxycholic acid is the traditional first-line treatment for PBC, with new medications like obeticholic acid and fibrates as second-line options, while PSC currently has no approved treatments except for liver transplants.
  • Recent advances include two new FDA-approved drugs for PBC and ongoing research into additional therapies for both PBC and PSC, showing promise for future treatments.
View Article and Find Full Text PDF
Article Synopsis
  • The study looked at how patients with a liver disease called primary biliary cholangitis (PBC) respond to a treatment called ursodeoxycholic acid (UDCA).
  • It found that many patients (33%) didn’t have a good response after one year, and those who lost their good response had a higher chance of needing a liver transplant or dying.
  • The research showed that staying or getting back to a good response is important for improving long-term health.
View Article and Find Full Text PDF
Article Synopsis
  • Tirzepatide is the first dual incretin receptor activator approved for treating type II diabetes and obesity.
  • It has shown benefits in reducing liver fat without known cases of liver damage from its use.
  • However, a case of elevated liver enzymes was reported in a 37-year-old woman with metabolic syndrome after using tirzepatide.
View Article and Find Full Text PDF

Inflammatory bowel disease (IBD) is a chronic condition characterized by immune-mediated inflammation in the gastrointestinal tract, which follows a relapsing and remitting course. Apart from affecting the gastrointestinal tract, IBD also has extra-intestinal manifestations (EIMs). While the etiology of extraintestinal manifestation remains unclear, it is theorized to be based on immunological responses influenced by genetic factors.

View Article and Find Full Text PDF

Background And Aims: Eosinophilic esophagitis (EoE) is a chronic immune-mediated inflammatory condition. Associated pathologies for EoE are similar to those with metabolic-dysfunction-associated steatotic liver disease (MASLD). This study assesses whether an association exists between MASLD and EoE.

View Article and Find Full Text PDF

Introduction: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with PBC improve with OCA therapy.

Methods: Patients randomized to OCA (5-10 mg) were compared with placebo (randomized controlled trial [RCT]) or external control (EC).

View Article and Find Full Text PDF

Fungal infections in liver cirrhosis.

Transl Gastroenterol Hepatol

June 2024

Division of Gastroenterology and Hepatology, University of California San Francisco, Fresno, CA, USA.

Liver cirrhosis is a chronic condition that is associated with a variety of complications across organ systems. Patients with cirrhosis also suffer from immune dysfunction, which may predispose them to catastrophic bacterial and fungal infections. Bacterial infections in liver cirrhosis have been well-documented, however, data remains scarce regarding fungal infections.

View Article and Find Full Text PDF
Article Synopsis
  • Despite improved treatments, colorectal cancer (CRC) still has high mortality rates, but some evidence points to aspirin (ASA) potentially lowering CRC incidence and metastasis.
  • A study of over 814,000 CRC patients revealed that those using ASA had significantly lower rates of total and gastrointestinal metastasis compared to non-users.
  • Results showed that ASA users had better outcomes even after adjusting for factors like age and other health conditions, although more research is needed to understand how it works and how long treatment should last to be effective.
View Article and Find Full Text PDF

Background And Aims: There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those without T2DM in biopsy-proven metabolic dysfunction-associated steatotic liver disease. We examined LSM progression in participants with T2DM versus those without T2DM in a large, prospective, multicenter cohort study.

Approach And Results: This study included 1231 adult participants (62% female) with biopsy-proven metabolic dysfunction-associated steatotic liver disease who had VCTEs at least 1 year apart.

View Article and Find Full Text PDF
Article Synopsis
  • This phase 1b study assessed the safety and effectiveness of cilofexor, a drug targeting farnesoid X receptors, in patients with compensated cirrhosis caused by primary sclerosing cholangitis over 12 weeks.
  • Patients received increasing doses of cilofexor, and while most reported side effects like pruritus and fatigue, there were no serious adverse events.
  • Results showed significant improvements in liver function markers, indicating that cilofexor may help manage cholestasis in these patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined the significance of changes in liver stiffness measurements (LSM) via vibration-controlled transient elastography (VCTE) in patients with non-alcoholic fatty liver disease (NAFLD), particularly focusing on progression to compensated advanced chronic liver disease (cACLD) and its association with liver-related events (LREs).
  • Out of 1,403 participants, 29% progressed to LSM ≥10 kPa, while 44% showed regression to LSM <10 kPa; those who progressed had a significantly higher rate of LREs (16%) compared to those who did not (4%).
  • The findings indicate that monitoring changes in LSM can be a non-invasive
View Article and Find Full Text PDF

Cannabis, one of the most widely used recreational drug in the United States, has had a significant surge in usage following its legalization in 1996. In recent years, there has been research into the physiological effects of cannabis on the gastrointestinal (GI) system. Our study aims to systematically examine the association between cannabis use and complications of gastroesophageal reflux disease (GERD).

View Article and Find Full Text PDF
Article Synopsis
  • The PNPLA3 rs738409 variant is linked to an increased risk of major adverse liver outcomes (MALOs) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
  • In a study involving 2,075 adults, advanced fibrosis, older age, and type 2 diabetes significantly heightened the risk of developing MALOs, particularly in those carrying the G-allele variant.
  • The negative impact of the PNPLA3 variant on liver health is intensified by factors like advanced fibrosis, age over 60, type 2 diabetes, and female sex, highlighting the importance of these conditions in assessing liver disease risk.
View Article and Find Full Text PDF

Despite advancing treatment methods, esophageal cancer (EC) maintains a high mortality rate and poor prognosis. Through various mechanisms, aspirin has been suggested to have a chemopreventive effect on EC. However, the long-term impact, particularly regarding the rate of metastasis, needs to be further elucidated.

View Article and Find Full Text PDF

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of ursodeoxycholic acid. Up to 40% of patients do not, however, respond adequately to ursodeoxycholic acid and therefore still remain at risk of disease progression to cirrhosis.

View Article and Find Full Text PDF

Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease associated with inflammation, fibrosis, and destruction of intra- and extrahepatic bile ducts. Despite substantial recent advances in our understanding of PSC, the only proven treatment of PSC is liver transplantation. There is an urgent unmet need to find medical therapies for this disorder.

View Article and Find Full Text PDF

Background: The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. Primary care providers play a critical role in the screening, diagnosis, and management of MASLD and/or metabolic dysfunction-associated steatohepatitis (MASH), though they can face challenges in this setting, particularly where healthcare resources are limited and barriers to care exist. To address these challenges, several guidelines have been developed to provide evidence-based recommendations for the clinical assessment and management of patients with MASLD/MASH.

View Article and Find Full Text PDF

A Review of New Concepts in Iron Overload.

Gastroenterol Hepatol (N Y)

February 2024

Liver Institute Northwest, Seattle, Washington.

Iron overload disorders are conditions that can lead to increased body iron stores and end-organ damage in affected organs. Increased iron deposition most commonly occurs in the liver, heart, endocrine system, joints, and pancreas. Iron overload disorders may be caused by genetic or acquired causes (transfusion, dyserythropoiesis, and chronic liver disease).

View Article and Find Full Text PDF

Background: Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality among hospitalized patients, particularly those who are immunosuppressed. We aim to assess the outcomes of CDI among kidney transplant (KT) recipients.

Methods: Nationwide Inpatient Sample from 2016 to 2020 was used to identify patients with KT and stratify based on the presence of CDI.

View Article and Find Full Text PDF

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.

N Engl J Med

February 2024

From the Toronto Centre for Liver Disease, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto (G.M.H.); the Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento (C.L.B.), and CymaBay Therapeutics, Newark (K.Y., Y.-J.C., D.B.C., C.A.M.) - both in California; the University of Texas Southwestern Medical School, Dallas (M.J.M.), and the Departments of Medicine and Surgery, Baylor College of Medicine, Houston (J.M.V.) - both in Texas; the Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland (A.E.K.); Liver Institute Northwest, Seattle (K.V.K.); the Division of Digestive Health and Liver Diseases, University of Miami, Miami (C.L.); the Liver Autoimmunity Unit, Hospital Italiano de Buenos Aires, Buenos Aires (A.V.); Centro de Investigación y Gastroenterología, Mexico City (A.L.L.G.C.); the Department of Basic Medical Sciences, Faculty of Public Health in Bytom, Medical University of Silesia, Bytom, Poland (E.J.); the Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (E.Z.); the Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University, College of Medicine, Seongnam, South Korea (S.-H.J.); the Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey (Y.Y.); Barts Liver Centre, Blizard Institute, Queen Mary University of London, London (Y.K.); the Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, French Network for Rare Liver Disease in Children and Adults FILFOIE, European Reference Network RARE-LIVER, Saint-Antoine Hospital and Research Center, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris (C.C.); Liver Centre Hamburg at Ifi-Institute, Hamburg, Germany (P.B.); the Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan-Bicocca, and the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori - both in Monza, Italy (P.I.); the Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBEREHD, European Reference Network on Hepatological Diseases (ERN-LIVER), University of Barcelona, Barcelona (M.C.L.H.); and Saberg Clinical Research, the Hague, the Netherlands (S.B.). Dr. Hirschfield is the Lily and Terry Horner Chair in Autoimmune Liver Disease Research at Toronto General Hospital.

Article Synopsis
  • Seladelpar, a medication aimed at treating primary biliary cholangitis, was tested in a phase 3 trial involving patients who didn't respond well to the standard treatment, ursodeoxycholic acid.
  • The trial showed that a significantly higher percentage of patients taking seladelpar achieved a biochemical response and normalized alkaline phosphatase levels compared to those on placebo.
  • Additionally, seladelpar was more effective in reducing itchiness, with patients reporting greater relief from pruritus than those receiving placebo, although some adverse events were noted.
View Article and Find Full Text PDF